Enhanced melanoma cancer prevention by novel melanotropins
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsVictor J. Hruby, Minying Cai
Life of this patent
Estimating the term…
Abstract
A gamma-melanocyte stimulating hormone (γ-MSH) derivative having improved stability, selectivity and bioavailabilty. The γ-MSH derivative is selective for the melanocortin-1 receptor (MC1 R) and is deliverable to skin cells via topical or transdermal delivery. The γ-MSH derivative is made up of naturally occurring amino acids for stimulating melanin from within for photoprotection of human skin against ultraviolet radiation damage.
Claims24
A melanocortin 1 receptor (MC1R) peptide ligand comprising naturally occurring amino acids, wherein the MC1R peptide ligand is according to SEQ ID NO. 1:
- (SEQ ID NO:
- 1)
- H-Tyr1-Val2-Waa3-Gly4-Xaa5-Phe6-Yaa7-Zaa8-Asp9-
- Arg10-Phe11-Gly12-R1
- wherein Waa is a Met, Ile, or Leu, Xaa is a His or Pro, Yaa is an Arg or Leu, and Zaa is a Phe or Trp, and wherein R1 of the C-terminal is —NH2, or —OH, with the caveat that Waa is not Met, Xaa is not His, Yaa is not Arg, Zaa is not Trp, and R1 is not —OH simultaneously.
(canceled)
(canceled)
A pharmaceutical composition for preventing skin cancer, said composition comprising a melanocortin 1 receptor (MC1R) peptide ligand in a pharmaceutically acceptable carrier, wherein the MC1R peptide ligand comprises naturally occurring amino acids, wherein the MC1R peptide ligand is according to SEQ ID NO. 1:
- (SEQ ID NO:
- 1)
- H-Tyr1-Val2-Waa3-Gly4-Xaa5-Phe6-Yaa7-Zaa8-Asp9-
- Arg10-Phe11-Gly12-R1
- wherein Waa is a Met, Ile, or Leu, Xaa is a His or Pro, Yaa is an Arg or Leu, and Zaa is a Phe or Trp, and wherein R1 of the C-terminal is —NH2, or —OH, with the caveat that Waa is not Met, Xaa is not His, Yaa is not Arg, Zaa is not Trp, and R1 is not —OH simultaneously, and wherein the MC1R peptide ligand is selective for MC1R, and wherein the MC1R peptide ligand is an agonist of MC1R, wherein the MC1R peptide ligand is capable of stimulating melanin production, thereby preventing skin cancer.
A pharmaceutical composition for stimulating melanin production, said composition comprising a melanocortin 1 receptor (MC1R) peptide ligand in a pharmaceutically acceptable carrier, wherein the MC1R peptide ligand comprises naturally occurring amino acids, wherein the MC1R peptide ligand is according to SEQ ID NO. 1:
- (SEQ ID NO:
- 1)
- H-Tyr1-Val2-Waa3-Gly4-Xaa5-Phe6-Yaa7-Zaa8-Asp9-
- Arg10-Phe11-Gly12-R1
- wherein Waa is a Met, Ile, or Leu, Xaa is a His or Pro, Yaa is an Arg or Leu, and Zaa is a Phe or Trp, and wherein R1 of the C-terminal is —NH2, or —OH, with the caveat that Waa is not Met, Xaa is not His, Yaa is not Arg, Zaa is not Trp, and R1 is not —OH simultaneously, and
- wherein the MC1R peptide ligand is selective for MC1R, and wherein the MC1R peptide ligand is an agonist of MC1R, wherein the MC1R peptide ligand is capable of stimulating melanin production.
(canceled)
-28. (canceled)
The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is in a form selected from a group consisting of a gel, a hydrogel, a water-in-oil emulsion, an oil-in-water emulsion, a cream, a lotion, an ointment, a spray, a foam, a multi-emulsion, and a liposome.
The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is in a form of a patch, said patch comprising an impenetrable outer layer, and a permeable inner layer, wherein the outer layer and the inner layer form a reservoir for storing the pharmaceutical composition, wherein when the patch is applied on a skin of mammal, the pharmaceutical composition permeates through the inner layer and the MC1R peptide ligand pass through the skin.
Dependencies are inferred from the claim text.